Rhythm Pharmaceuticals Inc【RYTM】株式ニュース | ADVFN

US Dollar vs Yen

登録してリアルタイムのチャート、分析ツール、価格を入手してください。

登録

ホーム
投資
株式
アメリカ
NASDAQ
Rhythm Pharmaceuticals Inc (RYTM)
Rhythm Pharmaceuticals Inc (RYTM) ニュース

Rhythm Pharmaceuticals Inc (RYTM)

56.23

0.00

(0.00%)

終了 11月18日 6:00AM

0.00

0.00

(0.00%)

取引時間後: -

リアルタイムのディスカッションと取引のアイデア: 当社の強力なプラットフォームで自信を持って取引できます。

プレミアム

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4/A - Statement of changes in beneficial ownership of securities: [Amend]

Rhythm Pharmaceuticals Announces Publication of Results from Phase 3 Study of Setmelanotide in Patients Between 2 and 5 Years Old in The Lancet Diabetes & Endocrinology

BOSTON, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global...

Rhythm Pharmaceuticals Announces New Employment Inducement Grants

BOSTON, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage...

Form 144 - Report of proposed sale of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 144 - Report of proposed sale of securities

Form 144 - Report of proposed sale of securities

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Rhythm Pharmaceuticals Announces Participation in Upcoming Investor Conferences

BOSTON, Nov. 06, 2024 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global...

Form 8-K - Current report

Rhythm Pharmaceuticals Reports Third Quarter 2024 Financial Results and Business Update

-- Third quarter 2024 net revenue from global sales of IMCIVREE® (setmelanotide) of $33.3 million -- -- Adult...

Rhythm Pharmaceuticals Announces Five New Data Presentations at ObesityWeek® 2024

-- Real-world data showed mean BMI decrease of 12.8% in adult patients with acquired hypothalamic obesity (N=8...

Rhythm Pharmaceuticals and Axovia Therapeutics Announce Joint Research Collaboration in Bardet-Biedl Syndrome

BOSTON and LONDON, Oct. 24, 2024 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM) and Axovia...

Monksdream

Monksdream 2週前

Monksdream

Monksdream 2月前

RYTM approaching a 52=week high

Monksdream

Monksdream 9月前

RYTM new 52 week high

Monksdream

Monksdream 9月前

RYTM new 52 week high

Monksdream

Monksdream 11月前

RYTM new 52 week high

Monksdream

Monksdream 12月前

RYTM new 52 week high

midastouch017

midastouch017 2年前

In my view ORMP is better than RYTM from investment perspective.

Sigh, how wrong can one be!
(including me - of course)

bandit007

bandit007 2年前

Why am I the only one posting here? This thing has been steady up over100% since I started posting here. Even on a day like today when most others are red. Another green day here!! $RYTM

bandit007

bandit007 2年前

When $20 breaks and holds this will fly! IMO

bandit007

bandit007 2年前

Looking like it’s ready to move up again here. Possible bounce off of support.

Amatuer17

Amatuer17 2年前

Some you win some you lose - I had a lot of conviction but later lost faith after that time and sold completely.

Laszlo1

Laszlo1 2年前

bandit007

bandit007 2年前

Thanks for posting. Breakout mode! GL

conix

bandit007

bandit007 2年前

I’m liking the chart on this one.

willlbone

willlbone 2年前

Two year slide continues.

Amatuer17

Amatuer17 3年前

I lost money on RYTM and booked losses already.

midastouch017

midastouch017 3年前

In my view ORMP is better than
RYTM from investment perspective.

Spot on!

Amatuer17

Amatuer17 4年前

In my view ORMP is better than RYTM from investment perspective.

The current market capon $255 million allows it to be a 10 bagger ($2.55 B) - speciall that it has first in class product and huge unmet market.

RTYM also has first in class product with unmet needs but it is rare disease and not many outside US can afford

Amatuer17

Amatuer17 4年前

Agree - it is good company
Will take time to make money but proof of product is there.

The valuation is fair at this point - upside maybe 50-70% by end of the year based on how they price and are able show sale.

The payment cycle with insurance will be key as the product is very high priced -

fishhunter

fishhunter 4年前

I started building a major position. And already a little green!
Quite the biotech soon last couple weeks= opportunity!

Amatuer17

Amatuer17 4年前

For some reason it is tanking now -sale the news

midastouch017

midastouch017 4年前

RYTM is not cheap as it has market cap of $832 million for pre-revenue biotech - so it is richly valued.

Are you kidding? You know what the mc is today?

Market Cap 1.737B

Since you introduced me to this company it has doubled
in price, if it was richly valued then, what is it now?

But this is besides my previous point - namely i 'missed'
the entry point.

Amatuer17

Amatuer17 4年前

You can actually wait for some time and buy - this is a long term play

midastouch017

midastouch017 4年前

I missed out this one!

Amatuer17

Amatuer17 4年前

Just amazing results - they are starting new basket trials.

The product is approved for one indication so it is now label expansion - the pricing power is amazing. This should really take off. Is it next Alexion in terms of rare disease treatment and pricing power?

Amatuer17

Amatuer17 4年前

Head the conf call - It was good call.

The results are much better that what PR said. Slide 14-15 shows correct numbers which were clarified by them.

Real numbers
Total patients - 31
Total BBS patients - 28
No of patients dropped - 4
Total no of patients relevant - 24

No of patients with 5%+ weight reduction - 16 = 67% that is double the number compared to combined number of 34.5%

No of patients who lost more than 10% weight - 11 out of 24 (45.8%)
Mean reduction - 14.5%

Compared to 1st approval which had few hundred population, BBS has 1000-1500 target population in US alone

This is large population for rare disease - @ $200k per year - this is a big market.

Also this is not a gene therapy - so drug is needed forever and it keeps the weight down.

Last point - All genes targeted in basket trial are in BBS category (strong or very strong relationship) so they think the basket trial results may be positive.

Cash enough till 2022. I think if stock goes down further, it will be good opportunity to buy - stock could give 50% returns from here in 6 months based on basket trial results.

Amatuer17

Amatuer17 4年前

Phase 3 results - BBS stat significant -AL not

Market reaction is not good. Conf call will give more info

https://finance.yahoo.com/news/rhythm-pharmaceuticals-announces-positive-topline-120000038.html

Amatuer17

Amatuer17 4年前

Finally - Approval

“Rhythm Pharmaceuticals Announces FDA Approval of IMCIVREE™(setmelanotide) as First-ever Therapy for Chronic Weight Management in Patients with Obesity Due to POMC, PCSK1 or LEPR Deficiency”

Another good news - voucher that they can sell or use for next approval

“With this approval, the FDA issued a Rare Pediatric Disease Priority Review Voucher (PRV) to Rhythm. The PRV can be redeemed to receive priority review for any subsequent marketing application or sold or transferred to other companies for their programs.”

https://finance.yahoo.com/news/rhythm-pharmaceuticals-announces-fda-approval-123000486.html

grich1

That’s a big run with PDUFA being in November. I took some profit but still in the game and will buy 100% back if reversal. Outstanding shares only @ 44M and float 30M. PT @ $33.

midastouch017

midastouch017 4年前

Amatuer17

Amatuer17 4年前

What is happening? Looks good

midastouch017

midastouch017 4年前

Not so sure the last few years.

I am no US citizen, i would not like to comment
about US politics. We have enough political
unrest in my part of the globe, in Israel.

I’ve done enough DD on PSTI and RDHL

I was a heavy investor in PSTI, sold it all a few
weeks ago at a big loss, and not looking back.

RDHL, otoh is a serious company, i am sure it will
go places, high places that is.

As for RYTM, I have no funds at the moment, but
will start a position soon.

GLTY

Amatuer17

Amatuer17 4年前

RYTM is not cheap as it has market cap of $832 million for pre-revenue biotech - so it is richly valued.

It has 70 employees - more than many biotech at this stage but not sufficient for marketing the drug. So they have to find a partner or go with buyout.

The good news is - the co has $228 milllion plus cash and it will allow them to run till end of 2021.

They are in niche area and there is no other competition nearby. If the drug can address genetic obesity - they have 80,000 target audience in US alone.

If the drug can be tested on genetic obesity/weight loss, it will be gold mine.

pennyrich

pennyrich 4年前

Not so sure the last few years. But what the heck.
I’m new on RYTM. I’ve done enough DD on PSTI and RDHL to hold a small 500 share stake in both. I’ll do some extra digging here because the stakes are much higher. The last 3 months haven’t been bad on the other two.
GLTUA
Pr

midastouch017

midastouch017 4年前

Sure. A free country, isn't it?

pennyrich

pennyrich 4年前

Can anyone play???

midastouch017

midastouch017 4年前

Thanks for the heads up Amatuer17,
i'll dig into it over the weekend.

Amatuer17

Amatuer17 4年前

Welcome to the board. Hope we all make money

This is a PDUFA based play

PDUFA date - 27th Nov

Disease - rare disease - obesity based on genetics

MOA - impacts the MC4PA gene that controls obesity and hunger. They have 4 more trials for other sub areas also in advance stage.

As per conf call - they are looking at pricing from $200k to $400k per year Patient population for this approval - around 1000

https://ir.rhythmtx.com/static-files/fd4e0919-4d82-47e0-afe3-8cd9b5151490

Rhythm Pharmaceuticals

The Limestone Boat

First Trust Senior Float...

Marathon Petroleum

Delayed Upgrade Clock

顧客サポート: +44 (0) 203 8794 460 | support@advfn.com

ADVFNのサービスをご利用いただくには、利用規約